GCSH

Across TCGA pan-cancer cohorts, GCSH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GCSH data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GCSH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GCSH expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, HNSC, and GBM are the cancer types where GCSH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.262	0.458	.006	30	view →
HNSC	DFS	Tertile	II,III,IV	0.892	1.000	.005	24	view →
GBM	DFS	Tertile	All	0.869	0.639	<.001	19	view →
LUAD	OS	Median	II,III,IV	0.893	0.453	.026	6	view →
LSCC	DFS	Median	II,III,IV	0.794	0.565	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GCSH–PDAC (DFS)

Open the PDAC breakdown →